Generating an Env protein which mimics the native conformation is a long sought goal in HIV/AIDS vaccine development since the use of monomeric gp120 in clinical trials ended in failures with the exception of RV144 phase III clinical trial that showed a modest efficacy of 31.2% [11]. The gene discussed is ERVW-1; the disease is AIDS.